Caris Life Sciences Inc.
CAI | NASDAQ
$32.77
-$1.56 (-4.54%)
Nov 2, 2026, 12:17 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q1 2024 Mar 31, 2024 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cash & Equivalents | 690.92M | 821.15M | 797.8M | 753.22M | 718.93M | 31.2M | 63.95M | 121.59M | 47.03M | 38.81M | 47.91M |
Short-Term Investments | 102.2M | 2.32M | 2.3M | 2.27M | 2.25M | 2.23M | 2.2M | n/a | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 56.73M | 46.2M | 45.35M | 46.99M | 41.08M | 39.36M | 5.89M | n/a | 851.9M | 800.21M | 661.54M |
Receivables | 116.89M | 90.52M | 112.14M | 26.7M | 50.89M | 80.17M | 88.24M | n/a | 190.81M | 166.1M | 152.77M |
Inventory | 123.79M | n/a | n/a | 49.3M | 40.61M | 36.55M | 39.57M | n/a | n/a | n/a | n/a |
Other Current Assets | 5.11M | 100.2M | 85.57M | 4.1M | 4.06M | 9.16M | 8.2M | -121.59M | 4.75M | 6.01M | 6.39M |
Total Current Assets | 1.06B | 1.01B | 997.8M | 854.25M | 833.32M | 171.23M | 215.73M | n/a | 242.59M | 210.92M | 207.07M |
Property-Plant & Equipment | 95.72M | 82.67M | 63.17M | 64M | 61.32M | 61.65M | 102.77M | n/a | 2.17B | 1.94B | 1.81B |
Goodwill & Intangibles | 19.34M | 19.34M | 19.34M | 19.34M | 19.34M | 19.34M | 19.34M | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 171.79M | 148.21M | 127.86M | 130.33M | 121.74M | 120.35M | 128.01M | n/a | 3.02B | 2.74B | 2.47B |
Total Assets | 1.23B | 1.16B | 1.13B | 984.57M | 955.06M | 291.58M | 343.73M | n/a | 3.27B | 2.96B | 2.68B |
Account Payables | 85.99M | 69.8M | 39.21M | 29M | 28.73M | 24.23M | 27.79M | n/a | 3.44M | 4.38M | 3.23M |
Deferred Revenue | 20.52M | n/a | n/a | n/a | 5.34M | 7.66M | n/a | n/a | 9.72M | 2.44M | 3.26M |
Short-Term Debt | 178K | 6.01M | 169K | 164K | 95K | 60.09M | 60M | n/a | 161.75M | 116.43M | 183.88M |
Other Current Liabilities | -26.88M | 68.09M | 87.77M | 2.79M | 13.84M | 33.48M | 7.47M | n/a | 163.58M | 343.79M | 88.15M |
Total Current Liabilities | 191.44M | 143.9M | 127.15M | 86.03M | 90.18M | 162.55M | 165.42M | n/a | 338.49M | 467.04M | 278.52M |
Long-Term Debt | 392.97M | 381.4M | 378.82M | 376.3M | 373.61M | 316.64M | 319.2M | n/a | 2.1B | 1.71B | 1.64B |
Other Long-Term Liabilities | 53K | 53K | 42.39M | 53K | 380K | 2.38B | 97.41M | 19.67M | 2.43M | 2.99M | 3.47M |
Total Long-Term Liabilities | 446.45M | 425M | 421.21M | 420.18M | 411.97M | 2.73B | 455.5M | 19.67M | 2.13B | 1.73B | 1.67B |
Total Liabilities | 637.89M | 568.9M | 548.36M | 506.21M | 502.15M | 2.89B | 620.92M | 19.67M | 2.47B | 2.2B | 1.95B |
Total Debt | 452.4M | 430.96M | 378.99M | 426.74M | 418.98M | 419.83M | 424.26M | n/a | 2.26B | 1.82B | 1.83B |
Book Value | 591.73M | 593.49M | 577.31M | 478.36M | 452.9M | -2.6B | -277.19M | -19.67M | 800.72M | 756.26M | 726.21M |
Book Value Per Share | 2.09 | 2.10 | 1.99 | 1.61 | 1.64 | -10.20 | -0.99 | -0.07 | 3.14 | 2.97 | 41.42 |
Common Stock | 283K | 284K | 283K | 283K | 282K | 38K | 38K | n/a | 2K | 2K | 2K |
Retained Earnings | -2.55B | -2.55B | -2.55B | -2.63B | -2.66B | -2.58B | -2.47B | n/a | 605.94M | 562.2M | 531.66M |
Comprehensive Income | 529K | 893K | 936K | 748K | 669K | 245K | -26.25M | -2.14B | 175K | 96K | 1.37M |
Shareholders Equity | 591.73M | 593.49M | 577.31M | 478.36M | 452.9M | -2.6B | -277.19M | -19.67M | 800.72M | 756.26M | 726.21M |
Total Investments | 102.2M | 2.32M | 2.3M | 2.27M | 2.25M | 2.23M | 2.2M | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove CAI